By HANA KAHLEOVA
Nearly each week, a affected person asks me some model of the identical query. If medicine like Ozempic work by copying a hormone my intestine already makes, can the best meals do what the injection does?
Meals and complement entrepreneurs have already answered sure. Frozen dinners now carry GLP-1 Friendly badges. Complement advertisements promise the drug’s results in a capsule. Hundreds of products invoke the hormone, aimed on the roughly 12 percent of U.S. adults who’ve taken considered one of these drugs. But the time period has no federal definition. The U.S. Division of Agriculture, which has permitted the phrase on some labels, has stressed that its approvals don’t create a normal. In March, Kyle Diamantas, then the Meals and Drug Administration’s prime meals official and now its performing commissioner, told Bloomberg Law the company was conscious of the problem however had no motion deliberate.
The result’s a advertising and marketing declare that borrows the identify of a hormone, falls between three regulators and has been examined by none of them. For a well being system nonetheless deciding who ought to get these medicine and who ought to pay for them, that isn’t a aspect challenge. It shapes what sufferers assume they’ll purchase as an alternative.
What the Science Helps
As a scientific researcher who research eating regimen and sort 2 diabetes, I believe the trustworthy reply is extra fascinating than the label. Meals actually can elevate the physique’s personal GLP-1. The hormone is launched by cells lining the gut inside minutes of a meal and, hours later, in response to compounds intestine micro organism make from fiber.
However the proof doesn’t help single-ingredient claims. A scoping review published in July gathered 52 trials of remoted fibers. Most examined a single dose, the standard trial enrolled 19 folks, and fewer than a 3rd discovered any rise in GLP-1.
The strongest sign my colleagues and I’ve discovered got here from an entire meal. In a randomized crossover trial, 60 males, 20 of them with sort 2 diabetes, ate two breakfasts with the identical energy and proportions of carbohydrate, protein and fats: a tofu burger with inexperienced tea, or a processed pork-and-cheese burger with a sweetened latte. After the plant-based meal, GLP-1 secretion was 30.5 % greater within the males with diabetes, and measures of insulin secretion and beta-cell function improved. The meals additionally differed in fiber, saturated fats and sugar, so we can’t say which distinction mattered. What moved the hormone was a sample of consuming, not a molecule.
Even the order of meals on a plate issues. In a small crossover trial in Japan, folks with sort 2 diabetes who ate fish or meat quarter-hour earlier than rice had greater GLP-1 ranges, slower abdomen emptying and smaller blood sugar swings than once they ate the rice first. None of those results comes from a product, and none of them suits on a sticker.
There may be additionally a restrict that issues for any declare of equivalence. The GLP-1 the intestine makes survives solely a minute or two within the bloodstream. The medicine are engineered to resist breakdown and hold the receptor occupied across the clock, at ranges the physique by no means produces by itself. A meal delivers a pulse. A weekly injection delivers a gentle flood.
A Declare Between Three Regulators
Every company with a stake in these labels has a instrument that might handle them. None is getting used.
The USDA’s Meals Security and Inspection Service must approve special statements and claims on meat and poultry labels before they are used. That provides it a gatekeeping position the opposite businesses lack. But FSIS has permitted GLP-1 claims with out saying what they imply, and as of June, 5 corporations had filed 21 extra label requests for meat and poultry merchandise.
The FDA governs most different meals and dietary supplements, however its framework gives little resistance. Typical meals makers could make structure/function claims with out notifying the company. Complement makers want solely notify the FDA inside 30 days of selling and add a disclaimer that the company has not evaluated the declare. A label saying a product helps GLP-1 can match comfortably in that area, even when it implies one thing nearer to treating weight problems or diabetes. The company has not been idle on GLP-1 advertising and marketing. It has despatched repeated rounds of warning letters to telehealth corporations over deceptive claims about compounded variations of the medicine. However that marketing campaign targets drug sellers. The meals and dietary supplements that borrow the hormone’s identify haven’t drawn the identical scrutiny.
The Federal Commerce Fee polices promoting. Its 2022 Health Products Compliance Guidance says well being claims require competent and dependable scientific proof, typically randomized, managed human trials, and in some instances a examine of the particular product quite than an remoted ingredient. Few GLP-1 advertising and marketing claims seem to satisfy that bar. The fee has proven it can act on this market: final December it finalized an order in opposition to a telehealth firm over unsubstantiated weight-loss claims and faux evaluations tied to the medicine. It has declined to say whether or not it’s taking a look at meals and complement claims.
Why It Issues
This isn’t a innocent sticker. A client who sees GLP-1 Pleasant on a frozen pizza could assume it does one thing it was by no means examined to do. A affected person who believes a capsule can stand in for a prescription could cease a drug she wants; one weight problems doctor advised Bloomberg Legislation she had simply seen precisely that. And a affected person on the drug could miss what meals can genuinely provide: a greater hormone response, steadier blood sugar and actual fullness.
What Clinicians and Payers Can Do
The sufferers most uncovered to those claims are sometimes those who can’t get the drug. In keeping with the Enterprise Group on Well being, the share of huge employers masking GLP-1 medicine for weight administration fell from 72 percent in 2025 to 60 percent this year, and 14 % have dropped that protection or plan to in 2027. When protection ends, the demand doesn’t. A few of it can land within the complement aisle, the place labels promise the drug’s impact for the worth of a bottle.
Clinicians can shut a part of that hole within the examination room. We already ask sufferers which dietary supplements they take. We must always ask particularly about merchandise bought as GLP-1 boosters or drug alternate options, particularly when a affected person has stopped a GLP-1 or misplaced protection for one. As I argued here recently, brief visits make the prescription the default. Additionally they depart little time to ask what a affected person purchased on the best way residence. That query opens the dialog about what meals can actually do.
Payers could make the trustworthy model simpler to succeed in. A plan that drops a drug and gives nothing instead leaves sufferers to the entrepreneurs. Medicare covers medical nutrition therapy just for folks with diabetes or kidney illness, or a kidney transplant prior to now 36 months. Many employers that also cowl the medicine already require sufferers to affix a weight administration program. These applications, and plans which have dropped protection, ought to pay for counseling with a registered dietitian, so sufferers be taught what a meal can do for their very own hormone response whether or not or not they keep on the drug.
Three Fixes
First, FSIS ought to cease approving GLP-1 claims till it defines them, and any definition ought to require human proof: examined on the product, measuring the hormone itself, on the quantity folks truly eat.
Second, the FDA ought to challenge steerage stating that claims evaluating a meals or complement to GLP-1 medicine, or promising drug-like results on weight or blood sugar, are implied illness claims quite than construction/operate claims. That will transfer essentially the most deceptive claims out of the evenly policed class they now occupy.
Third, the FTC ought to apply its present substantiation commonplace to GLP-1 advertising and marketing, beginning with warning letters to essentially the most aggressive complement claims. It doesn’t want new authority to take action.
Higher nonetheless, the three businesses ought to coordinate, so {that a} declare can’t escape scrutiny by shifting from a meat label to a complement bottle to a web based advert.
Many years of analysis have taught us that GLP-1 is a sign with a timescale, a location and a dose. A sticker flattens all three. Meals can do greater than most individuals assume, and fewer than the labels promise. Sufferers, and the clinicians and well being plans who take care of them, deserve the trustworthy model of each.
Hana Kahleova, MD, PhD, is a doctor board-certified in inside drugs, endocrinology and way of life drugs, and director of scientific analysis on the Physicians Committee for Responsible Medicine, a nonprofit that promotes plant-based diet and preventive drugs. She led the plant-based meal research described right here and experiences no monetary relationships with meals, complement or pharmaceutical corporations.
